Published Report - Medical Foods for Inborn Errors of Metabolism Market to Grow at a CAGR of 11.2% to reach US$ 5,768.79 Mn Million from 2020 to 2027

  • Report Code : TIPAR00011389
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 243

Medical Foods for Inborn Errors of Metabolism Market to Grow at a CAGR of 11.2% to reach US$ 5,768.79 Million from 2020 to 2027

Buy Now

The medical foods for inborn errors of metabolism market was valued at US$ 2,507.80 million in 2019 and it is projected to reach US$ 5,768.79 million in 2027; it is expected to grow at a CAGR of 11.2% from 2020 to 2027.

Medical food refers to the specialized kind of food formulated to be consumed under physician supervision and intended for specific dietary management of a particular disease or condition. These medical conditions usually have distinctive nutritional requirements based on scientific and recognized principles that are established by medical evaluation. The medical food differs from drugs; however they are intended for consumption under the medical supervision as a primary intervention. When infants are identified with inborn errors of metabolism, they are usually prescribed a special diet suitable to their particular condition that must be followed for the lifetime. The growth of the global medical foods for inborn errors of metabolism market is attributed to the increasing incidence of inborn errors of metabolism and increasing preference towards dietary food supplements. However, limitations associated to medical foods for inborn errors of metabolism is the major factor hindering the market growth.

The global medical foods for inborn errors of metabolism market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Published Report - Medical Foods for Inborn Errors of Metabolism Market: Strategic Insights

Published Report - Medical Foods for Inborn Errors of Metabolism Market
  • CAGR
    CAGR (2019 - 2027)
    11.2%
  • Market Size 2019
    US$ 2.51 Billion
  • Market Size 2027
    US$ 5.77 Billion

Market Dynamics

GROWTH DRIVERS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
FUTURE TRENDS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
OPPORTUNITIES
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX

Key Players

  • Nestl Health Science
  • Nutricia
  • Solace Nutrition
  • Abbott
  • Mead Johnson and Company LLC
  • BioMarin Pharmaceutical
  • Ajinomoto Cambrooke Inc
  • Poa Pharma
  • PKU MDmil

Regional Overview

Regional Overview
  • North America
  • Europe
  • Asia-Pacific
  • South and Central America
  • Middle East and Africa

Market Segmentation

Market SegmentProduct
  • Amino Acid
  • Glytactin with GMP
  • Amino Acid-Modified Infant Formula with Iron
  • Low-Calcium/Vitamin D-Free Infant Formula with Iron
  • Low Protein Food
Market SegmentAge group
  • Infants
  • Weaning
  • Adolescent
  • Adults
Market SegmentDisease
  • Phenylketonuria
  • Maple Syrup Urine Disease
  • Homocystinuria
  • Urea Cycle Disorders
  • Methylmalonic Acidemia
  • Organic Acidurias
  • Propionic Acidemia
  • Isovaleric Acidemia
  • Disorders of Leucine Metabolism
  • Glutaric Acidemia Type I
  • Renal Disease
  • Tyrosinemia Types I and II
Market SegmentForms
  • Powder
  • Liquids
  • Gels
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

 

Market Insights

Growing Preference toward Dietary Supplements to Drive Global Medical Foods for Inborn Errors of Metabolism Market Growth

The rates for consumption of nutraceutical supplements and prescribed medical food are increasing over enzyme-based therapeutic medicines. The increasing costs of healthcare and rising preference of consumers toward simple and effective remedies for disease management are likely to be responsible for the changing lineage from medicines toward medical supplements and nutritional foods. Medical food refers to a category of products that are used in dietary management of various diseases including inborn errors of metabolism that contains specific nutrients to fulfill the nutrient requirements for patients suffering from particular conditions.

The US Food and Drug Administration (FDA) have categorized medical food under four major categories formulas for metabolic disorders, complete nutritional products, nutritionally incomplete products, and oral rehydration solutions. 

The medical foods are easy to be accessed as they do not require a prescription but are necessarily consumed under a medical supervision. In case of inborn errors of metabolism, medical foods are used as treatment options, and the products available in the market are regulated under authoritative and regulatory food and diet supplement statuses. The nutritional treatment for inborn errors of metabolism provides between 85% and 90% of nutritional requirement for a person suffering from a particular inherited disorder. Moreover, there are almost negligible side effects of these supplements, making them ideal for consumption for patients of all age groups. In recent years, the private medical insurers in the US and a few other countries are also offering reimbursement programs for the consumption of certain medical foods. Thus, the rising adoption of medical food and nutrient supplements is expected to foster the market growth over the years to come.

Product -Based Insights

In terms of product type, the global medical foods for inborn errors of metabolism market is segmented into amino acids, glytactin with GMP, amino acid-modified infant formula with iron, low calcium/vitamin-D infant formula with iron, low protein food and others. In 2019, the amino acid segment held largest share of the market. Also, the same segment is estimated to register the highest CAGR during the forecast period.

Age group -Based Insights

In terms of age group, the global medical foods for inborn errors of metabolism market is segmented into infants, weaning, adolescents and adults. In 2019, the infants segment held largest share of the market. Also, the same segment is estimated to register the highest CAGR during the forecast period.

Disease -Based Insights

Based on disease, the global medical foods for inborn errors of metabolism market is segmented into phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystonuria, urea cycle disorders, methylmelonic academia, organic acidureas, propionic academia, isovaleric academia, disorders of leucine metabolism, glutaric academia type-1, renal disease, tyrosinemia types I and II and others. The phenylketonuria segment held the largest market share in 2019. However, the glutaric academia type-1 segment is expected to grow at the fastest rate during the coming years.

Forms -Based Insights

Based on forms, the global medical foods for inborn errors of metabolism market is segmented into powder, liquids, gels, and others. The powder segment held the largest market share in 2019. Also, the same segment is estimated to grow at the highest CAGR during the forecast period.

Packaging-Based Insights

In terms of packaging, the global medical foods for inborn errors of metabolism market is segmented into can, jar, packet, bottle, and others. The can segment held the largest share of the market in 2019. However, the packets segment is expected to grow at the highest CAGR during the forecast period.

Distribution Channel -Based Insights

In terms of distribution channel, the global medical foods for inborn errors of metabolism market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, drug stores and others. The retail pharmacies segment held the largest share of the market in 2019. Also, the same segment is estimated to grow at the fastest rate during the forecast period.

The global medical foods for inborn errors of metabolism market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

Medical Foods for Inborn Errors of Metabolism Market Report Scope

Report Attribute Details
Market size in 2019 US$ 2.51 Billion
Market Size by 2027 US$ 5.77 Billion
Global CAGR (2019 - 2027) 11.2%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By Product
  • Amino Acid
  • Glytactin with GMP
  • Amino Acid-Modified Infant Formula with Iron
  • Low-Calcium/Vitamin D-Free Infant Formula with Iron
  • Low Protein Food
By Age group
  • Infants
  • Weaning
  • Adolescent
  • Adults
By Disease
  • Phenylketonuria
  • Maple Syrup Urine Disease
  • Homocystinuria
  • Urea Cycle Disorders
  • Methylmalonic Acidemia
  • Organic Acidurias
  • Propionic Acidemia
  • Isovaleric Acidemia
  • Disorders of Leucine Metabolism
  • Glutaric Acidemia Type I
  • Renal Disease
  • Tyrosinemia Types I and II
By Forms
  • Powder
  • Liquids
  • Gels
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Nestl Health Science
  • Nutricia
  • Solace Nutrition
  • Abbott
  • Mead Johnson and Company LLC
  • BioMarin Pharmaceutical
  • Ajinomoto Cambrooke Inc
  • Poa Pharma
  • PKU MDmil
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

 

Global Medical Foods for Inborn Errors of Metabolism Market – by Product

  • Amino Acid
  • Glytactin with GMP
  • Amino Acid-Modified Infant Formula With Iron
  • Low-Calcium/Vitamin D-free Infant Formula With Iron
  • Low Protein Food
  • Others

Global Medical Foods for Inborn Errors of Metabolism Market – by Age Group

  • Infants
  • Weaning
  • Adolescents
  • Adults    

Global Medical Foods for Inborn Errors of Metabolism Market – by Disease

  • Phenylketonuria(PKU)
  • Maple Syrup Urine Disease(MSUD)
  • Homocystinuria
  • Urea Cycle Disorders
  • Methylmalonic Acidemia
  • Organic Acidurias
  • Propionic Acidemia
  • Isovaleric aciDemia
  • Disorders of Leucine Metabolism
  • Glutaric Acidemia Type I
  • Renal Disease
  • Tyrosinemia Types I and II
  • Others

Global Medical Foods for Inborn Errors of Metabolism Market – by Forms

  • Powder
  • Liquid
  • Gels
  • Others

Global Medical Foods for Inborn Errors of Metabolism Market – by Packaging

  • Can
  • Jar
  • Packets
  • Bottle
  • Others 

Global Medical Foods for Inborn Errors of Metabolism Market – by Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Drugstores
  • Others

Global Medical Foods for Inborn Errors of Metabolism Market – by Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East & Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South America and Central America (SCAM)
    • Brazil
    • Argentina
    • Rest of SCAM

Company Profiles

  • Nestlé Health Science
  • Abbott
  • Reckitt Benckiser Group Plc
  • Ajinomoto Cambrooke, Inc.
  • Solace Nutrition
  • Primus Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical
  • Danone SA
  • Galen Limited
  • PKU-MDmil
Report Coverage

Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered

Segment Covered

Product ; Age group ; Disease ; Forms ; Packaging ; Distribution Channel ; and Geography

Regional Scope

Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope

Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


What is the regional analysis in terms of medical foods for inborn errors of metabolism market?

North America is the largest market for the medical foods for inborn errors of metabolism market. The factors that are responsible for the dominance of the region include rising government support well-developed healthcare facilities, presence of top market players, increasing number of patients with inborn errors of metabolism and rising awareness regarding benefits of consuming nutritional supplements under medical supervision. Similarly, in Canada, increasing government initiatives to raise awareness regarding rare genetic disorders and well-established healthcare infrastructure are leading to market growth. Asia-Pacific is anticipated to register as the fastest-growing region in the global medical foods for inborn errors of metabolism market. The growth of the market is expected to be fastest in countries such as China, India, and Japan. The factors that are expected to drive the market growth include large number of patients suffering with genetic diseases and increasing launch of innovative products by local players in the Asian countries. Increasing collaborations and partnerships are also responsible for the growth of the market in the Asian region.

What are medical foods for inborn errors of metabolism?

Medical food refers to the specialized kind of food formulated to be consumed under physician supervision and intended for specific dietary management of a particular disease or condition. These medical conditions usually have distinctive nutritional requirements based on scientific and recognized principles that are established by medical evaluation. The medical food differs from drugs; however they are intended for consumption under the medical supervision as a primary intervention. When infants are identified with inborn errors of metabolism, they are usually prescribed a special diet suitable to their particular condition that must be followed for the lifetime.

What are the driving factors for the medical foods for inborn errors of metabolism market across the globe?

Factors such as increasing incidence of inborn errors of metabolism and increasing preference towards dietary food supplements are expected to boost the growth of the global medical foods for inborn errors of metabolism market. However, the market is likely to get impacted by the limitations associated to medical foods for inborn errors of metabolism during the forecast period.

The List of Companies - Medical Foods for Inborn Errors of Metabolism Market 

  1. Nestlé Health Science
  2. Nutricia
  3. Solace Nutrition
  4. Abbott
  5. Mead Johnson and Company, LLC.
  6. BioMarin Pharmaceutical
  7. Ajinomoto Cambrooke, Inc.
  8. Poa Pharma
  9. PKU-MDmil
  10. Primus Pharmaceuticals, Inc.

Trends and growth analysis reports related to Pharmaceuticals : READ MORE..